A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancerKimberly Blackwell, M. S. Berger, Janet Maleski et al.|Journal of Clinical Oncology|2004Cited by 90
A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancerKim T. Blackwell, M. S. Berger, Eli Kaplan et al.|Journal of Clinical Oncology|2004Cited by 44